510(k) for BioStar's flu diagnostic kit:
This article was originally published in Clinica
The FDA has cleared BioStar's rapid test for influenza for sale in the US. FLU OIA uses an optical immunoassay technology, developed by the Santa Fe, New Mexico-based company, to detect both influenza A and influenza B within 20 minutes. The test was developed as a collaboration between BioStar, which was recently acquired by Thermo BioAnalysis, and Australian company Biota Holdings
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.